a of in commercial solid years you, and progress was quarters positioning Sera Fiscal for the good afternoon, continued growth Prognostics in year Peter, and XXXX Thank everyone. ahead.
new data and payer support will that business we the publicized recently in we our adding growth more incremental have progress During periods. new of believe made contracts XXXX, future in
year, in was seeing nominal revenue growth are we for percentage Although volumes. our the test
year-over-year six-fold units versus QX it XXXX XXXX For the for increase was and XX-fold. versus total XXXX, XXXX, was
Of course, from in baseline are XXXX. increases small a these
commercial in positive our testing it terms physician adoption are of response, takes single XXXX. relationship, Ultimately, time, volumes of both we results from published reimbursement we execute PreTRM we traction to we further is the growing to that numbers from tests. to broaden data our is our payer should and biggest strategy growth of payers, of reporting of new clinical -- seeing during we to increased time demonstrate that's new strong share by and first technology continues in look early this forward data have at publication This and While of way additional value our and our the strong technology in the studies. compelling result manifested the accelerate by adopters And while strategy. use
systems. In focus we've of maintained early continued terms a on adopter customers,
systems delivery IDNs, groups. physician networks For example, hospital practice integrated or and
systems, to PreTRM adopter permitted as selective data, by with the by PreTRM these ways early discussing implement of in not but work We bringing course them making strategy announcements continue their only within with to anticipate We testing the systems. into sharing institutions. the also test-and-treat
point of time, revenue growing number the take future quarters relationships While ahead increases may our among in multiple believe and customers the rescale we inflection these among implementations there accordingly. customers amount as be tests an of where
growing build volumes quest to our while our our in is reducing among these availability help event important up broaden PreTRM Another and to customers testing testing costs business.
in patients' successful ambient December. for a we system validation only touched which PreTRM quarter, last blood collection costs. more end, on commercially where transport that testing, it reducing sites easily transport reduces to I of the labs, need collected our for dry be but can and launched the also ice our an expands by of This For not the availability for blood number
shipping proportion year. note And is Just in moments of will newly growing that years ordered as to that come. these as contribute this of over the a collection being now shipping ambient tests we from volume to and deployed even months ambient continue test launch, importantly, to it we early believe increases next
help to of Let's published new babies. our improve to data body growing of now mothers the turn supporting mission and the
study. an the test evidence the is strong for PreTRM ACCORDANT the use Sera’s part Building First, important strategy. of of
publication results Spontaneous the Economics, be Risk care or serving the disparities, that study published TREETOP of the specific QX, illustrates disadvantaged populations. and pharmaceutical that populations maternal Preterm study. Health most on PreTRM with utility without of the health its a care in announced in clinical showcased Finding from during in or clinical enhanced management, to enable made Results prenatal and was a ACCORDANT, where treatment test rigorous effective ethnic modeling real In medical better we neonatal management cost Journal by combining strategy the of length hospital Predictor This effectiveness with stay. based Multicenter test-and-treat the utility better of economic of racial terms indicated healthcare from Sera’s addressing analysis. benefits outcomes. reducing progress Assessment and the may and analysis impact of XXX in of ACCORDANT, underserved women secondary work study
detailed neonatal in a endpoints, significant bit mortality A AVERT test-and-treat and the few benefit -- results the our announced data the and believe showed large We clinical of we scientific we both believe these measured additional analyses life. of AVERT new strategy, being AVERT line health PreTRM results a PRETERM results the prepared morbidity our secondary these multi the and to the reviewed bode strategy length TRIAL, PreTRM better solidify that index. vulnerable a Now, study announcement submission neonatal as PRIME we of large TRIAL, controlled on giving top test-and-treat in TRIAL. for for composite prospective babies months. PRETERM the coming supporting the ago, start for results, statistically AVERT The that In improve results peer we of its stronger weeks center, are a study. subgroup the including at by in improvements well the help most a those these believe journal our outcomes mentioned neonatal of to which chance randomized top-line of very stay, primary hospital endpoints
patients, take on-track during pleased place there to interim the the we are this surpassed PRIME delay X,XXX the We believe required that And parts year. are that interim number thing, though that look. can this enrolled pre-planned enable to announce has to analysis is moving
results well to describe evidence different for strategy to by like minute we a AVERT pieces bode broader in would I our take believe why of how fit top-line PRIME. together clarifying
studies reduction in co-primary both length have morbidity First, neonatal of mortality. hospital decreased identical, stay endpoints: and and neonatal
socioeconomic heavy demographic profiles. broad, representative a pre-existing racial, and a diverse Second, is of that studies both risk
intervention Third, the or prescribed same multimodal similar. are the in protocols clinical strategies of studies both the
of for consists clinical the a progesterone additional same monitoring risk Care test aspirin, and intensive identified Specifically, form education higher higher care PreTRM of be the this includes management dose and of low to more at delivery. of use frequent mothers patients. management premature by risk more for the
sites. the between a and other is while direction. in these It potential give was differences these that, point for the cell similarities out PRIME few, study, the optimism weigh clinical us which a to PRIME that differences trial's AVERT the PRIME could administration study single the To PRETERM note is TRIAL over AVERT lead involves to always possible performed across also of could protocol XX while important within adherence the system, to sites, there in and
As in been another patients who and during waned. PRIME reached ended will have while difference, and treated after pandemic COVID the treated Delaware locally pandemic patients term in before prevalent AVERT in early, others the some was has study the substantially all were
design. design Finally, a PRIME generated in of that the of PRETERM controlled evidence historically the study the AVERT randomized is prospective, of terms And is controlled TRIAL. stronger
though final historical statistical studies the see arm clinical subjects analysis at as study of interim Xx for includes was readout. before better in XX,XXX statistically of the it for to at have study. designed are approximately of many the level outcomes treatment the at size power powered helps almost that, the analysis, PRIME XX% look the larger the AVERT its PRIME and much Furthermore, test perspective to to interest, and approximately provide is enrollment. that the included AVERT Oftentimes, a In fully statistical controls, trial enrolled The primary power power at effects power. higher even twice of full arm study full PRIME in as higher many enrollment. and look as approximately is interim The
enroll of know outcome overseeing usually given also encouraging proceed the are met. important continue believe to should monitoring continuing what which to or the inadvisable. original of it's good must early clearly Considering their because recommend look results analysis the of AVERT Sera's are PreTRM to cases pre-specified of rarely wait these which many in the we enrollment predictive we enrollment either and whether then ending are that enrollment PRIME factors, analysis and is that and at patients -- extent numbers that the must allows enrollment to interim results group support not other studies study -- endpoints while time differences trial, the look look regard, reasons, and happens recognize to final test-and-treat are And studies external The PRIME's occurs. completely these number final study results to most determine continuing for the trial interim In a enough interim the they we that await strategy.
as We of as study and from are resulting to look results the encouraged can. soon prospective sharing by thus you forward we with the PRIME studies data far, controlled the
pipeline. biomarker Sera's on word a Now
update Lastly, let biomarker pipeline. me moment take a on pregnancy to our you
expectant and the most all preeclampsia balance In most with more proactive poses a incompletely to at preeclampsia impacted for preterm of preeclampsia preeclampsia need physician baby. for newborn to our the another. X% pregnancy, health and of week informed developed clinical The the more one deliver mother. the to of and advance X% of mothers enables for making time a decision is expectant goals of these is About pregnancies Specifically, management. preeclampsia decision Identification among the XXth can babies. well a challenging at occurring when outcomes problem clinical and before by against there's mothers. sizable which an be the severe Preterm in are deteriorating prediction. adverse cases odds before medical that serious preeclampsia, occurs, serious rapidly Medical that
clinically data submit scientific reviewed peer Late shortly now being year, or public to of prepared is the journal. preeclampsia the successfully scientific manuscript we last validated data validation and a the to in preterm made the prediction community, publication the and
is groundbreaking validated we only valuable. believe asymptomatic, patient our preeclampsia on the preeclampsia is and a As rigorously predictor preterm that work when
when pregnancy will and portfolio tests We provide Sera’s and patients. valuable that information of broader commercially determine doctors how into it the gets to
enable In the summary, are of extend implement to as we strategy our foundation commercial continuing build solid carefully our to us we runway. also to work to data
during to pleased to see it are We progress continue this year. and the expect strongly
call of results. for Jay I'll a now the to over review quarter fourth financial turn our
